R
0.079
0.00 (1.28%)
| 前收盘价格 | 0.078 |
| 收盘价格 | 0.080 |
| 成交量 | 256,239 |
| 平均成交量 (3个月) | 292,537 |
| 市值 | 22,404,164 |
| 股市价格/股市净资产 (P/B) | 4.42 |
| 52周波幅 | |
| 利润日期 | 21 Feb 2025 |
| 营业毛利率 | -68.73% |
| 营业利益率 (TTM) | 20.71% |
| 稀释每股收益 (EPS TTM) | -0.010 |
| 季度收入增长率 (YOY) | 87.30% |
| 总债务/股东权益 (D/E MRQ) | 3.25% |
| 流动比率 (MRQ) | 4.88 |
| 营业现金流 (OCF TTM) | -2.12 M |
| 杠杆自由现金流 (LFCF TTM) | -2.23 M |
| 资产报酬率 (ROA TTM) | -33.68% |
| 股东权益报酬率 (ROE TTM) | -71.10% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (AU) | 混合的 | 混合的 |
| Diagnostics & Research (全球的) | 看跌 | 看跌 | |
| 股票 | RHYTHM BIO FPO [RHY] | - | - |
AIStockmoo 评分
-1.6
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | -3.5 |
| 技术振荡指标 | -4.0 |
| 平均 | -1.63 |
|
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 27.93% |
| 机构持股比例 | 6.18% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合